FOURIER Evolocumab reduces CV events regardless of baseline LDL statin intensity

PHILADELPHIA A subanalysis of the FOURIER trial presented at the National Lipid Association Scientific Sessions found that evolocumab was linked to reduction in CV events regardless of a patients LDL or intensity of statin therapy at baseline. Marc S...